A randomized, crossover trial comparing the efficacy and safety of fesoterodine and extended-release oxybutynin in children with overactive bladder with 12-month extension on fesoterodine: The FOXY study.
CONCLUSIONS: The use of fesoterodine or oxybutynin appears as safe and effective for the treatment of OAB in children. Based on our study, long-term treatment to achieve the ultimate goal of urinary continence is needed in this population.
PMID: 31977308 [PubMed - as supplied by publisher]
Source: Canadian Urological Association Journal - Category: Urology & Nephrology Authors: Ramsay S, Naud É, Simonyan D, Moore K, Bolduc S Tags: Can Urol Assoc J Source Type: research
More News: Canada Health | Cardiology | Children | Constipation | Electrocardiogram | Heart | Overactive Bladder | Overactive Bladder Syndrome | Oxybutynin | Pediatrics | Statistics | Study | Urology & Nephrology